Literature DB >> 30355152

Pathology and Pathogenesis of Chagas Heart Disease.

Kevin M Bonney1, Daniel J Luthringer2, Stacey A Kim2, Nisha J Garg3, David M Engman2.   

Abstract

Chagas heart disease is an inflammatory cardiomyopathy that develops in approximately one-third of people infected with the protozoan parasite Trypanosoma cruzi. One way T. cruzi is transmitted to people is through contact with infected kissing bugs, which are found in much of the Western Hemisphere, including in vast areas of the United States. The epidemiology of T. cruzi and Chagas heart disease and the varied mechanisms leading to myocyte destruction, mononuclear cell infiltration, fibrosis, and edema in the heart have been extensively studied by hundreds of scientists for more than 100 years. Despite this wealth of knowledge, it is still impossible to predict what will happen in an individual infected with T. cruzi because of the tremendous variability in clonal parasite virulence and human susceptibility to infection and the lack of definitive molecular predictors of outcome from either side of the host-parasite equation. Further, while several distinct mechanisms of pathogenesis have been studied in isolation, it is certain that multiple coincident mechanisms combine to determine the ultimate outcome. For these reasons, Chagas disease is best considered a collection of related but distinct illnesses. This review highlights the pathology and pathogenesis of the most common adverse sequela of T. cruzi infection-Chagas heart disease-and concludes with a discussion of key unanswered questions and a view to the future.

Entities:  

Keywords:  Chagas; cardiomyopathy; heart; myocarditis; pathogenesis; trypanosome

Mesh:

Year:  2018        PMID: 30355152      PMCID: PMC7373119          DOI: 10.1146/annurev-pathol-020117-043711

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  178 in total

Review 1.  Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry.

Authors:  Edecio Cunha-Neto; Angelina M Bilate; Kenneth V Hyland; Simone G Fonseca; Jorge Kalil; David M Engman
Journal:  Autoimmunity       Date:  2006-02       Impact factor: 2.815

2.  Trypanosoma cruzi infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies.

Authors:  Daniela A Bermejo; María C Amezcua Vesely; Mahmood Khan; Eva V Acosta Rodríguez; Carolina L Montes; Maria C Merino; Kai Michael Toellner; Elodie Mohr; Dale Taylor; Adam F Cunningham; Adriana Gruppi
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

3.  Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients.

Authors:  Jian-jun Wen; Pedro C Yachelini; Adela Sembaj; Rafael E Manzur; Nisha Jain Garg
Journal:  Free Radic Biol Med       Date:  2006-04-26       Impact factor: 7.376

4.  5-lipoxygenase is a key determinant of acute myocardial inflammation and mortality during Trypanosoma cruzi infection.

Authors:  Wander R Pavanelli; Fredy R S Gutierrez; Flávia S Mariano; Cibele M Prado; Beatriz Rossetti Ferreira; Mauro Martins Teixeira; Cláudio Canetti; Marcos A Rossi; Fernando Q Cunha; João S Silva
Journal:  Microbes Infect       Date:  2010-04-08       Impact factor: 2.700

Review 5.  Evolution and pathology in chagas disease--a review.

Authors:  Antonio R L Teixeira; Rubens J Nascimento; Nancy R Sturm
Journal:  Mem Inst Oswaldo Cruz       Date:  2006-08       Impact factor: 2.743

Review 6.  Chagas heart disease pathogenesis: one mechanism or many?

Authors:  Kevin M Bonney; David M Engman
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

7.  The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies.

Authors:  M L Higuchi; C F De Morais; A C Pereira Barreto; E A Lopes; N Stolf; G Bellotti; F Pileggi
Journal:  Clin Cardiol       Date:  1987-11       Impact factor: 2.882

Review 8.  The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart.

Authors:  Raffaele Altara; Ziad Mallat; George W Booz; Fouad A Zouein
Journal:  J Immunol Res       Date:  2016-10-03       Impact factor: 4.818

Review 9.  The chronic gastrointestinal manifestations of Chagas disease.

Authors:  Nilce Mitiko Matsuda; Steven M Miller; Paulo R Barbosa Evora
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 10.  CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?

Authors:  Fernando Dos Santos Virgilio; Camila Pontes; Mariana Ribeiro Dominguez; Jonatan Ersching; Mauricio Martins Rodrigues; José Ronnie Vasconcelos
Journal:  Mediators Inflamm       Date:  2014-07-01       Impact factor: 4.711

View more
  55 in total

Review 1.  Chagas Disease in the United States: a Public Health Approach.

Authors:  Caryn Bern; Louisa A Messenger; Jeffrey D Whitman; James H Maguire
Journal:  Clin Microbiol Rev       Date:  2019-11-27       Impact factor: 26.132

Review 2.  Oxidative stress implications for therapeutic vaccine development against Chagas disease.

Authors:  Subhadip Choudhuri; Lizette Rios; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Expert Rev Vaccines       Date:  2021-08-30       Impact factor: 5.217

Review 3.  Chronic Chagas Disease-the Potential Role of Reinfections in Cardiomyopathy Pathogenesis.

Authors:  Christian Olivo Freites; Hendrik Sy; Amal Gharamti; Nelson I Agudelo Higuita; Carlos Franco-Paredes; José Antonio Suárez; Andrés F Henao-Martínez
Journal:  Curr Heart Fail Rep       Date:  2022-08-11

4.  Consensus Enolase of Trypanosoma Cruzi: Evaluation of Their Immunogenic Properties Using a Bioinformatics Approach.

Authors:  Alejandro Diaz-Hernandez; Maria Cristina Gonzalez-Vazquez; Minerva Arce-Fonseca; Olivia Rodríguez-Morales; Maria Lilia Cedillo-Ramirez; Alejandro Carabarin-Lima
Journal:  Life (Basel)       Date:  2022-05-18

Review 5.  Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death.

Authors:  Antonia Pino-Marín; Germán José Medina-Rincón; Sebastian Gallo-Bernal; Alejandro Duran-Crane; Álvaro Ignacio Arango Duque; María Juliana Rodríguez; Ramón Medina-Mur; Frida T Manrique; Julian F Forero; Hector M Medina
Journal:  Pathogens       Date:  2021-04-22

6.  Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.

Authors:  Daniel Musikant; Romina Higa; Cristina E Rodríguez; Martin M Edreira; Oscar Campetella; Alicia Jawerbaum; María S Leguizamón
Journal:  Biochimie       Date:  2021-04-20       Impact factor: 4.079

7.  Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.

Authors:  Xiaomo Li; Sijia Yi; Débora B Scariot; Santiago J Martinez; Ben A Falk; Cheryl L Olson; Patricia S Romano; Evan A Scott; David M Engman
Journal:  JCI Insight       Date:  2021-05-10

Review 8.  Risk of COVID-19 in Chagas Disease Patients: What Happen with Cardiac Affectations?

Authors:  Alejandro Diaz-Hernandez; Maria Cristina Gonzalez-Vazquez; Minerva Arce-Fonseca; Olivia Rodriguez-Morales; Maria Lilia Cedilllo-Ramirez; Alejandro Carabarin-Lima
Journal:  Biology (Basel)       Date:  2021-05-06

9.  A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease.

Authors:  André Azevedo Reis Teixeira; Luis Rodriguez Carnero; Andréia Kuramoto; Fenny Hui Fen Tang; Carlos Hernique Gomes; Natalia Bueno Pereira; Léa Campos de Oliveira; Regina Garrini; Jhonatas Sirino Monteiro; João Carlos Setubal; Ester Cerdeira Sabino; Renata Pasqualini; Walter Colli; Wadih Arap; Maria Júlia Manso Alves; Edécio Cunha-Neto; Ricardo José Giordano
Journal:  iScience       Date:  2021-05-15

10.  Circulating miR-146a as a possible candidate biomarker in the indeterminate phase of Chagas disease.

Authors:  Martha Alicia Ballinas-Verdugo; Rogelio Frank Jiménez-Ortega; Eduardo Martínez-Martínez; Nancy Rivas; Erick Abraham Contreras-López; Roxana Carbó; Fausto Sánchez; Rafael Bojalil; Ricardo Márquez-Velasco; Fausto Sánchez-Muñoz; Ricardo Alejandre-Aguilar
Journal:  Biol Res       Date:  2021-07-21       Impact factor: 5.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.